多肽质量控制的传统观点是纯度百分比
多肽质量控制, 在大多数购买对话中, 表示一个数字: 分析证书上的纯度数字, 通常写为“>95%”. 逻辑很简单. 百分比越高意味着产品越清洁, 更清洁的产品更好.
巴赫姆发布的等级阶梯是这一逻辑最清晰的表达. 公司的 氨基酸和肽质量控制指南 推荐 >95% NMR 纯度, 晶体学及其作为定量酶底物参考的用途, 受体-配体和阻断研究; 90-95%用于单克隆抗体生产和体内或体外定量工作;>80% 用于定性蛋白质印迹和磷酸化研究; 和 免疫级 (>65%) 用于多克隆抗体生产.
这是一个将产品与应用程序相匹配的可靠框架. 这也是, 在实践中, 许多买家采用的唯一标准.
要点: 纯度简写是供应商等级约定, 不是监管要求.
纯度简写从何而来
等级源自供应商目录及其价格阶梯, 未见于任何药典专论. 没有专着需要单一标题纯度值作为购买决定的基础, 这就是为什么研究级肽纯度测试必须根据数字背后的方法而不是仅根据数字来判断.
为什么仅用纯度百分比无法作为肽质量控制标准
纯度数字不是材料的属性. 它是在一组特定条件下运行的一种特定方法产生的面积百分比, 这种区别是大多数肽质量控制论点悄然崩溃的地方.
问题 1: 该数字是方法定义的. 一个裸露的“>95%” 不会告诉您任何有关色谱柱化学成分和尺寸的信息, 流动相和梯度, 流量, 进样量, 检测波长, 运行时间, 积分规则, 或者溶剂前沿是否被排除. 改变其中任何一个，同一个小瓶就会产生不同的数字. 两个实验室报告同一批次的不同纯度并不一定是对该材料的争议; 这可能是关于方法的争议. 任何没有这些参数的研究级肽纯度测试结果都是不可重复的, 并且您无法重现的结果不是规格.
问题 2: 大众认同并不纯粹. LC-MS 结合色谱分离证实了准确的分子量, MALDI-TOF 提供快速完整质量指纹识别. 但 MALDI-TOF 对复杂混合物的处理能力较弱, 其中矩阵峰值, 盐和加合物效应, 和离子抑制干扰, 它给出了有限的序列信息. MS/MS 提供碎片离子序列信息并可以定位修改, 虽然肽图谱提供基于消化的序列覆盖，但可能会错过部分覆盖和不稳定修饰. 这些方法都不能可靠地量化相对成分. 仅靠精确质量无法解析每个同量异位或异构体对 (肽表征方法, 检索到的 2026-05-11).
问题 3: 纯度并不能检测到真正有害的污染物. 美国药典 <71> 无菌测试仅涵盖活微生物. 不检测内毒素, 残留溶剂, 或残留的TFA, 并且 HPLC 纯度数据也无法检测到其中的大多数. 这些是具有不同规格的单独测试, 这就是为什么可购买的 QC 包会单独说明它们: 内毒素保证≤0.01 EU/μg，TFA 降低至 <10%, 低至 <1% (金斯瑞 AccuPep+QC). 纯度百分比对所有这些都保持沉默.
第四层是前三层的复合体. 净肽含量并非纯度: NPC 测量相对于非肽材料的肽, 主要是抗衡离子和水分, 而纯度包括肽污染物, 所以两者不等价. 即使在高纯度下，富含碱性氨基酸和亲水性的肽也有望实现低 NPC, 并且纯度本身因批次而异, 订购的肽 80% 可能从任何地方交付 80% 到 100% (巴亨质量控制指南).
EMA 的合成肽指南, 六月生效 2026, 将杂质控制视为必须“通过批次数据进行科学论证”的事情, 不仅仅是与理论阈值对齐,”并将肽相关杂质分解为指定的已识别物质, 指定未识别, 未指定, 和总类别，而不是将它们折叠成一个数字 (EMA合成肽指南, 检索到的 2026-06-14).
合在一起, 这三个问题指向同一个方向: 纯度百分比所回答的问题比大多数买家认为的要窄得多. 它描述了一种方法对材料一维的看法, 并且对身份保持沉默, 按顺序, 关于反离子, 关于水分, 以及带来实际风险的污染物.
数据实际上表明了肽质量控制失败的情况
记录的失败是身份, 标签和污染物故障, 没有边际纯度不足. 在 2026, 维多利亚州首席卫生官将六例急性肝毒性病例与未经批准的标有瑞他鲁肽的肽产品联系起来, 注意到临床表现表明“可能有其他污染物造成” (RACGP新闻GP, 22 六月 2026). 到八月底, 七名维多利亚州患者在使用假冒瑞他鲁肽后因急性肝毒性住院, 堪培拉卫生服务中心报告了肝损伤，但未公布计数 (美国广播公司新闻, 24 八月 2026). 两份报告均将污染原因表述为假设, 尚未得到证实的发现.
服务 标签失败单独记录. FDA 记录了带有虚假标签信息的复合产品, 包括标注从未配制过该产品的药店的标签, 并指出索马鲁肽钠和索马鲁肽醋酸盐等盐形式“与批准药物中使用的活性成分不同” (美国FDA, 已更新 9 一月 2026).
一起阅读, 这些指出了肽质量控制应实际测试的五个标准: 身份确认, 使用声明的方法进行纯度测试, 肽杂质分析, 贴标精度, 和肽供应链可追溯性. 每一项都必须由特定的文档字段来证明, 不是通过断言.
阅读执行记录但不要过度阅读
网上流传的执法计数需要范围. 公民六月 2026 分析计数 14 FDA 自 12 月起发出警告信 2024 销售瑞他鲁肽的公司, 并发现截至五月 2026, 11 的 14 继续为瑞他鲁肽或其他未经批准的肽做广告，同时 8 继续销售瑞他鲁肽 (公众公民, 16 六月 2026). 该审查是倡导组织自己的, 并且这些信件没有被独立地叙述.
同样的分析引用了芬里克, 商业测试服务, 为了 2,759 自 12 月起测试瑞他鲁肽样品 2024, 其中 71 的 179 供应商 (39.6%) 被评为“差”,“ “坏的,”或“欺诈” (公众公民, 16 六月 2026). Finnrick 的商业模式取决于对供应商的不信任, 它的抽样不是随机的, 并且评级背后的分析未指定. 此类数据因来源而异; 发现的方向比任何单一数字更可靠.
身份确认是第一个重要的肽质量控制测试
多肽合成 身份确认是发现 TGA 案件的测试, 因为小瓶 店铺 包含完全不同的分子. 纯度百分比无法检测到: 错误标记或取代的肽仍然可以返回干净的单峰色谱图.
The practical bar is accurate molecular mass by LC-MS with chromatographic separation, plus orthogonal confirmation by MS/MS fragmentation or peptide mapping for sequence-level coverage. Each method has blind spots worth knowing before you rely on it. MALDI-TOF spectra can carry matrix peaks, 盐和加合物效应, and ion suppression that shift or mask the true mass. Peptide mapping can miss partial sequence coverage and labile modifications.
对于小费: The peptide certificate of analysis should name the method used, report observed versus theoretical 合成肽 大量的, and state the sequence coverage achieved. If any of those three fields is missing, the identity claim is not checkable.
当前肽质量控制框架下的纯度测试和杂质分析
Purity testing and peptide impurity profiling are two separate tests with separate acceptance logic, and the current framework sets the impurity thresholds rather than leaving them to the supplier. The EMA’s synthetic-peptide guideline, 有效的 1 六月 2026, sets reporting, identification and qualification thresholds at >0.1%, >0.5% 和 >1.0% 分别, and states that ICH Q3A/Q3B do not apply to synthetic peptides (EMA 关于合成肽开发和制造的指南, 发表 9 December 2025). Those figures reached this article through a secondary summary whose own text says they should be confirmed against the primary guideline, and the primary PDF could not be read here, so treat them as a working reference and check the source document directly before you write them into a specification.
Impurity control is anchored to the Ph. 欧元. general monograph “Substances for Pharmaceutical Use”, and the guideline requires it to be scientifically justified by batch data rather than aligned to a theoretical threshold. That distinction matters when you read a certificate of analysis: the categories are specified identified, 指定未识别, unspecified and total, and a single “purity” figure collapses all four.
|
Impurity category |
What it covers |
Acceptance logic |
|---|---|---|
|
Specified identified |
Named impurity with a structure |
Individual limit set from batch data |
|
Specified unidentified |
Detected impurity, structure not assigned |
Individual limit set from batch data 关于 |
|
未指定 |
Any impurity not individually listed |
Common limit across the group |
|
Total |
Sum of all detected impurities |
Overall ceiling for the batch |
Non-peptide contaminants sit outside that table and need their own tests. Endotoxin is measured by USP <85> / 鲎试剂, sterility by USP <71>, residual solvents by headspace GC against ICH Q3C, the TFA counterion by ion chromatography, CE or ¹⁹F NMR, counterion identity by ion chromatography, and moisture by Karl Fischer titration. Commercial specifications are published, for example by GenScript, with endotoxin at ≤0.01 EU/µg and TFA held below 10%, down to below 1% for some grades.
One more number belongs in the same conversation: net peptide content is not purity. Low NPC is expected for basic and hydrophilic peptides even at high purity, and Bachem’s QC guide notes the batch-to-batch variability this creates, so both figures have to be considered when you prepare a solution.
标签和可追溯性完善了肽质量控制包
Peptide supply chain traceability is the criterion that makes every other test auditable, and it is the one buyers skip most often. A purity figure, an identity result and an impurity profile are only as good as the record that ties them to a specific vial.
A receiving record should capture the lot number, supplier identity, 收到日期, vial condition, shipping and storage conditions, and the version of the peptide certificate of analysis the shipment was matched against. The TGA’s September 2026 safety alert states that products supplied in unmarked vials, purchased online or obtained from overseas, are not subject to the same controls over the quality or efficacy of the goods when compared with medicines approved for supply in Australia.
Records built this way follow the ALCOA expectation: 可归因的, 清晰易读, 同时期的, original and accurate.
⚠️警告: A CoA that cannot be matched to a lot number and a receiving record is not traceability.
如何应用该肽质量控制框架
Start with the lot, not the catalogue. Before you place an order, ask the supplier for the full analytical and documentation package for the specific lot you would receive, and treat the catalogue purity figure as marketing until that package arrives.
-
Request the peptide certificate of analysis with method parameters. Ask for the chromatogram, the peak table, and the column, gradient and detection wavelength behind them. Quick win: same day.
-
Check identity evidence. Confirm the package reports observed versus theoretical mass and states sequence coverage. Quick win.
-
Check impurity reporting. Ask which thresholds the supplier applies for reporting, identifying and qualifying impurities, and whether batch-to-batch variability is described. Longer-term.
-
Confirm the non-peptide panel. 内毒素, 不育, 残留溶剂, counterion and moisture should be reported where your intended use requires them. Commercial QC specifications are published, and GenScript’s peptide quality control specifications illustrate the documented bar, including endotoxin limits and residual TFA ranges. Longer-term.
-
Verify traceability. Match lot number, label and receiving record. Quick win.
A complete package for one lot typically contains the CoA with method parameters, a representative chromatogram and peak table, identity data, impurity results against stated thresholds, the applicable non-peptide panel, and a lot number that matches the label and your receiving record. Bachem’s quality control guide describes how batch-to-batch variability and non-peptide content are handled, which is the level of detail worth asking for. MOL Changes supports this workflow by assembling analytical and lot documentation into a single reviewable package.
Measure two things: the proportion of lots arriving with a complete package, and the rate of discrepancies between the label and the CoA. Expect the first supplier comparisons to be decisive within one or two procurement cycles.
关于肽质量控制论点的警告
The strongest objection to this framework is that the trigger evidence is thin. The TGA’s September 2026 safety alert rests on laboratory testing of a single labelled-retatrutide vial, with no replicate count reported, and the RACGP’s clinical news coverage of the Victorian case clusters describes the contaminant cause as a hypothesis rather than a lab-confirmed finding.
Two things this research does not establish deserve stating plainly. No source here gives a verified purity percentage measured on a retatrutide-labelled retail sample, and no source gives a verified rate of end-user certificate-of-analysis forgery. The prevalence of the problem is unproven.
The conventional view also still holds in places. For early-stage qualitative work such as Western blotting, a lower-grade material with a documented method may be entirely adequate, and Bachem’s QC guide grade tiers remain a reasonable starting heuristic when the intended use is qualitative.
That is why the case for this peptide quality control framework is not scale. It is checkability: every criterion here can be verified against a document you already receive. 多肽生产
But doesn’t a higher purity grade solve this?
不, because a grade tier and an identity test answer different questions. A purity grade tells you how much of the material in the vial is the stated compound; it does not tell you that the stated compound is the one in the vial. The TGA’s September 2026 safety alert described an identity failure, and no purity grade would have detected a different molecule (TGA safety alert). Use both: a grade tier as a starting filter, identity confirmation as the test that actually closes the gap.
如果我已经仅就纯度对供应商进行了资格鉴定怎么办?
Nothing you have already bought needs to be discarded, and the qualification does not have to start over. Re-baseline the relationship instead: ask the supplier for the method-level documentation behind the lots you have already received, meaning the chromatographic method parameters and the chromatogram that produced the purity figure on the peptide certificate of analysis, not a reissued certificate with the same number on it.
That request is the whole transition, and the response is the finding. A supplier that cannot produce method parameters and a chromatogram for a past lot has told you something about how that lot was qualified, and about what the documentation will look like for the next one.
您如何回应这些标准适用于药品生产的论点, 不是研究用途?
The thresholds are written for pharmaceutical development, and that scope is real. The EMA guideline on synthetic peptides that took effect in June 2026 addresses manufacturers developing medicinal products, not suppliers selling research-grade material. But the mechanism it relies on transfers cleanly: the guideline asks manufacturers to justify their control strategy with batch data rather than to clear a blanket threshold. That is the same discipline a research buyer applies when scaling peptide impurity profiling to intended use, testing identity and the impurities that matter for the experiment instead of adopting the full pharmaceutical panel wholesale.
结论: 文档标准, 不是什么吓人的事
The retatrutide warning is best read as a documentation failure, not a purity failure, and the fix is a five-criterion package (身份确认, purity testing, 杂质分析, labelling, and traceability) rather than a higher purity number. That reframing matters because it changes what buyers ask for. Instead of requesting a better grade, purchasers can make method parameters, 色谱图, and lot records a condition of purchase, which makes suppliers who cannot produce them visibly distinguishable from those who can. The shift is already underway in adjacent regulated markets, where documentation completeness, not a headline percentage, separates qualified suppliers from unqualified ones.
If that standard becomes routine, a peptide certificate of analysis stops being a marketing artifact and becomes a checkable record: a document a reviewer can audit, not a number a buyer has to trust. That is the future state worth working toward, and it does not require new regulation to start. It requires buyers to ask better questions before they order.
后续步骤: Request a documentation package before your next peptide order. Ask for the method parameters behind the purity figure, the chromatogram it came from, and the lot record that ties the material to its test results. A supplier who can produce all three is a supplier you can qualify on evidence rather than on a number.
披露: MOL Changes provides peptide synthesis and quality documentation services, and has a commercial interest in the documentation standards described in this article.
